Comprehensive Study on CAR-T Cell Therapy Market 2020 to 2026 | Top Companies like - Bluebird Bio, Celgene Corporation, Gilead Sciences Inc., Servier Laboratories, Pfizer Inc., Amgen Inc., Novartis International AG, Johnson & Johnson.

Market Study Report recently introduced new title on "2020-2026 CAR-T Cell Therapy Market Report" that provides an in-depth overview of industry and competitive landscape, covering multiple market segments and elaborates market outlook and status to 2026.

The global CAR-T Cell Therapy market size is expected to reach USD 8.92 billion by 2026 growing at a CAGR of 34.5% from 2020 to 2026 according to a new study published by the marker research report. The report "CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen (CD19/CD22, BCMA, Others); By Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma (FL), Others); By Regions: Segment Forecast, 2020 - 2026" provides deep dive insights on the current market dynamics and gives a detailed analysis on future growth trends of this market.

Request a sample of this premium report at: https://www.marketstudyreport.com/request-a-sample/1695130/?openpr.com/&utm_medium=VIPin

According to the analysis by the marker research report, the potential of the market is ~ $9 billion by 2026, with major focus on Diffuse Large B-Cell Lymphoma (DLBCL) indication in 2020-21. However, it is expected that the market would also start focusing on Multiple Myeloma (MM) indication and the market for the same is expected to grow at a compounded annual growth rate of more than 80% from 2020 to 2026.

It can be seen that the business scenario of the market is dynamic and major companies are competing with each other to increase their market share in the major geographies of U.S. and Europe. For example, Novartis and Gilead came-up with 33 and 28 authorized centers respectively in U.S. Some of the major companies in this space such as Celgene are expected to file for FDA approvals for two more CAR-Ts lisocabtagene maraleucel in lymphoma and bb2121 (idecabtagene vicleucel) in myeloma.

Some major key players in global CAR-T Cell Therapy Market includes Bluebird Bio (US), Celgene Corporation (US), Gilead Sciences, Inc. (US), Cellectis (France), Servier Laboratories (France), Pfizer Inc. (US), Mereck KGaA (Germany), Amgen Inc. (US), Intellia Therapeutics (US), Novartis International AG (Swiss), Caribou Biosciences, Inc. (US), Celyad (Belgium), Bellicum Pharmaceuticals, Inc. (US), Noile-Immune Biotech (Japan), Nanjing Legend Biotechnology Co., Ltd. (China), Johnson & Johnson (US), Sangamo Therapeutics, Inc. (US) among others.

This market report focuses on CAR-T which is one of the most innovative therapy available in the market which uses the patients' immune cells to fight cancer. The WBCs (white blood cells) are extracted - reengineered - injected again into the patient body to fight the malignant cells. This novel therapy has joined the bandwagon of the cancer cure treatments and it is expected to be one the sought-after therapies in the market. Majority of the companies have already started investing in them to gain a better market share in this industry.

It is estimated that U.S. is one of the major markets for CAR-T Cell Therapy due to continuous R&D happening in this region also backed by ongoing regulatory approvals of the new therapies. Along with the new therapy developments, companies are also focusing on establishing centers for cancer awareness and how this novel therapy would help in cancer treatment. This would help the market to grow in this region. The European region is also expected to closely follow by U.S. wherein European Medicine Agencies (EMA) have approved Kymriah and Yescarta which is expected to push the market for further growth in this region. However, the market for Asia Pacific is at its early stages wherein Ministry of Health, Labor and Welfare (MHLW) of Japan is the first regulatory authority to approve Kymriah in APAC.

Along with opening new centers and acquiring necessary government approvals, the companies are also focusing on partnerships, acquisitions and mergers. For instance, Celgene acquired Juno Therapeutics in November 2018 for approximately $9 billion in 2018 and further Bristol-Myers Squibb completed its acquisition of Celgene in November 2019.

Request a discount on standard prices of this premium report at: https://www.marketstudyreport.com/check-for-discount/1695130/?openpr.com/&utm_medium=VIPin

Competitive Landscape and Key Vendors:
The marker research report has segmented the CAR-T Cell Therapy market report on the basis of Target Antigens, Indications, and Region

o CAR-T Cell Target Antigens Outlook (Revenue, USD Million, 2017 - 2026)
o CD19/CD22
o BCMA (B-Cell Maturation Antigen)
o Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13R?2, LewisY)
o CAR-T Cell Indication Outlook (Revenue, USD Million, 2017 - 2026)
o Diffuse Large B-Cell Lymphoma (DLBCL)
o Acute Lymphoblastic Leukemia (ALL)
o Chronic Lymphocytic Leukemia (CLL)
o Multiple Myeloma (MM)
o Follicular Lymphoma (FL)
o Others
o CAR-T Cell Regional Outlook (Revenue, USD Million, 2017 - 2026)
o U.S.
o Europe
o Japan
o Rest of the World UK
o France
o Italy
o Russia
o Rest of Europe

Table of Content:
1. Overview and Scope
1.1. Research goal & scope
1.2. Research assumptions
1.3. Research Methodology
1.3.1. Primary data sources
1.3.2. Secondary data sources
1.4. Key take-aways
1.5. Stakeholders
2. Executive Summary
2.1. Market Definition
2.2. Market Segmentation
3. CAR-T Cell Therapy Market - Premium Insights
3.1. CAR-T Cell Therapy- Industry snapshot
3.2. CAR-T Cell Therapy- Ecosystem analysis
3.3. CAR-T Cell Therapy Market dynamics
3.3.1. CAR-T Cell Therapy- Market Forces
3.3.1.1. CAR-T Cell Therapy Market driver analysis
3.3.1.2. CAR-T Cell Therapy Market restraint/challenges analysis
3.3.1.3. CAR-T Cell Therapy Market opportunity analysis
3.4. Industry analysis - Porter's five force analysis
3.5. CAR-T Cell Therapy Market PEST analysis, 2019
3.6. CAR-T Cell Therapy Industry trends

Related Report:
Global Cell Freezing Media for Cell Therapy Market Professional Survey Report 2020

The global Cell Freezing Media for Cell Therapy market is valued at USD 56.6 million in 2019 and is expected to reach USD 143 million by the end of 2026, growing at a CAGR of 13.7% between 2020 and 2026.

https://www.marketstudyreport.com/reports/global-cell-freezing-media-for-cell-therapy-market-professional-survey-report-2020?openpr.com/&utm_medium=VIPin

Contact Us:
Market Study Report LLC
4 North Main Street,
Selbyville, Delaware 19975
USA
Phone: 1-302-273-0910
US Toll Free: 1-866-764-2150
Email: sales@marketstudyreport.com
Website: https://www.marketstudyreport.com/
News: https://www.cuereport.com/

About Us:
Marketstudyreport.com allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.

This release was published on openPR.